RAPT Therapeutics, Inc.

69 articles with RAPT Therapeutics, Inc.

• RAPT Therapeutics Reports First Quarter 2022 Financial Results

  5/11/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today reported financial results for the quarter ended March 31, 2022.

• RAPT Therapeutics Expands Leadership Team with Multiple Key Hires

  5/4/2022

  RAPT Therapeutics, Inc. today announced the appointments of Gwen Carscadden as Chief Human Resources Officer, Jim Farmer as Vice President of Clinical Operations and Shari Geffon as Vice President of Program and Alliance Management.

• RAPT Therapeutics Announces Biomarker Data from Phase 1b Trial of RPT193 Consistent with Disease Modification in Atopic Dermatitis

  3/28/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced biomarker data from the company’s randomized placebo-controlled Phase 1b clinical trial of RPT193 in patients with moderate-to-severe atopic dermatitis (AD) were consistent with previously reported top-line data which showed clear improvement in key exploratory efficacy measures.

• RAPT Therapeutics Reports Fourth Quarter and Year End 2021 Financial Results

  3/10/2022

  RAPT Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2021.

• RAPT Therapeutics to Participate in the 11th Annual SVB Leerink Healthcare Conference

  2/9/2022

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will participate in a virtual fireside chat at the 11th Annual SVB Leerink Healthcare Conference on Wednesday, February 16, 2022 at 1:40 p.m. ET.

• RAPT Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

  1/4/2022

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, 2022 at 9:00 a.m. ET.

• RAPT Therapeutics Reports Third Quarter 2021 Financial Results

  11/10/2021

  RAPT Therapeutics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2021.

• RAPT Therapeutics Appoints Industry Veteran Lori Lyons-Williams to its Board of Directors

  11/9/2021

  RAPT Therapeutics, Inc., a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, announced the appointment of Lori Lyons-Williams, a 20-year industry veteran, to its Board of Directors.

• RAPT Therapeutics to Participate in Upcoming Investor Conferences

  11/8/2021

  RAPT Therapeutics, Inc. today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in November:  Stifel 2021 Virtual Healthcare Conference

• RAPT Therapeutics Announces Upcoming Oral Presentation of RPT193 Phase 1b Data at the 4th Inflammatory Skin Disease Summit

  10/18/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that it will present additional clinical efficacy data from its Phase 1b monotherapy trial of RPT193 in patients with moderate-to-severe atopic dermatitis at the 4th Inflammatory Skin Disease Summit.

• RAPT Therapeutics Announces Late-Breaking Oral Presentation of Positive Results from Phase 1b Trial of RPT193 at the 30th European Academy of Dermatology and Venereology Congress

  9/30/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy in 31 patients with moderate-to-severe atopic dermatitis (AD).

• RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress

  9/20/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced that it will present clinical safety and efficacy data from the RPT193 Phase 1b monotherapy trial in patients with moderate-to-severe atopic dermatitis.

• RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference

  9/20/2021

  RAPT Therapeutics, Inc. today announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the 2021 Cantor Virtual Healthcare Conference on Monday, September 27, 2021 at 2:00 p.m.

• RAPT Therapeutics to Present at Upcoming Investor Conferences in September 2021

  9/3/2021

  RAPT Therapeutics, Inc. announced that Brian Wong, M.D., Ph.D., President and CEO, will present at the following investor conferences in the first half of September.

• RAPT Therapeutics Reports Second Quarter 2021 Financial Results

  8/11/2021

  RAPT Therapeutics, Inc. today reported financial results for the second quarter and six months ended June 30, 2021.

• RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  6/18/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced the closing of its previously announced underwritten public offering of 4,356,060 shares of its common stock at a price to the public of $33.00 per share

• RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis

  6/14/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), today announced positive topline results from its randomized placebo-controlled Phase 1b clinical trial of RPT193 as monotherapy

• RAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference

  5/20/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced that Brian Wong, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Virtual Conference

• RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic DermatitisCompany Reaffirms Guidance to Report Data in 1H 2021

  3/22/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced enrollment has been completed in its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis (AD).

• RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results

  3/11/2021

  RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the fourth quarter and year ended December 31, 2020.